TrialThe pharmacogenomics journal2022

Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial.

Joseph P Schacht et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.